Application of experimental keratoconjunctivitis shigellosa in chemotherapeutic evaluation of rifampicin to bacillary dysentery.
D000818:Animals; D003315:Cornea / Q000473:pathology; D004195:Disease Models, Animal; D004405:Dysentery, Bacillary / Q000188:drug therapy*; D004847:Epithelial Cells; D004926:Escherichia coli; D005069:Evaluation Studies as Topic; D006168:Guinea Pigs; D007273:Injections, Intramuscular; D007612:Kanamycin / Q000627:therapeutic use; D007637:Keratoconjunctivitis / Q000188:drug therapy* / Q000209:etiology; D009883:Ophthalmic Solutions; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*; D012760:Shigella; D012763:Shigella flexneri; D013307:Streptomycin / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use
D009883:Ophthalmic Solutions; D007612:Kanamycin; D013752:Tetracycline; D012293:Rifampin; D013307:Streptomycin